BreezeBio (formerly Genedit) closed a $60 million financing to pivot its Nanogalaxy delivery platform into an internal therapeutic pipeline. The company said it will fund lead programs toward IND‑enabling studies, including an mRNA‑based tolerance program targeting Type‑1 diabetes and other delivery candidates for genetic medicines. The financing marks a transition from pure‑play delivery services to an asset‑backed strategy, reflecting investor appetite for companies that can both enable partner programs and capture value through internal assets. BreezeBio’s rebrand and funding arrive amid continued investor focus on delivery technologies as a gatekeeper for broader RNA/mRNA therapeutic success. Investors and competitors will watch whether BreezeBio’s delivery platform translates into differentiated clinical performance and whether the company can balance partnering with building its own clinical-stage assets.